Veloxis to Present Company Overview and Envarus® XR (tacrolimus extended-release tablets) Launch Update at Jefferies 2016 Healthcare Conference

Investor service announcement no. 4/2016

To: NASDAQ OMX Copenhagen A/S Hørsholm, Denmark, 8 June 2016

Veloxis to Present Company Overview and Envarus^® XR (tacrolimus extended-release tablets) Launch Update at Jefferies 2016 Healthcare Conference

Veloxis Pharmaceuticals A/S (OMX: VELO), a transplant-focused specialty pharmaceutical company currently launching Envarsus^® XR (tacrolimus extended-release tablets) for kidney transplant recipients in the US, announced that Mr. Craig Collard, the company’s President and Chief Executive Officer, is scheduled to present a company overview at the Jefferies 2016 Healthcare Conference in New York City on Thursday, June 9th at 11:00 am ET. Mr. Collard will be providing an update on the company, an overview of the market opportunity for Envarsus XR, and details about launch momentum in the US and in Europe. An archived edition of the presentation will be available on the Veloxis website, www.veloxis.com, shortly after the event.

For more information, please contact:
Craig A. Collard
President & CEO
Phone: +1 919 524 4317
Email: cac@veloxis.com

Veloxis Pharmaceuticals A/S (VELO)
Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Veloxis’ unique, patented delivery technology, MeltDose®, is designed to enhance the absorption and bioavailability of select orally administered drugs. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.
For further information, please visit www.veloxis.com.